IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v12y2022i1d10.1186_s13561-022-00392-w.html
   My bibliography  Save this article

Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims data of COVID-19 in 2020-2021

Author

Listed:
  • Ryan R. Nugraha

    (USAID Health Financing Activity/ThinkWell, LLC)

  • Mutia A. Pratiwi

    (USAID Health Financing Activity/ThinkWell, LLC)

  • Ruli Endepe Al-Faizin

    (USAID Health Financing Activity/ThinkWell, LLC)

  • Ardian Budi Permana

    (Ministry of Health)

  • Ery Setiawan

    (USAID Health Financing Activity/ThinkWell, LLC)

  • Yuli Farianty

    (Ministry of Health)

  • Kalsum Komaryani

    (Ministry of Health)

  • Hasbullah Thabrany

    (USAID Health Financing Activity/ThinkWell, LLC)

Abstract

Background Recent Coronavirus Disease-19 (COVID-19) pandemic shows that health system, particularly hospital care, takes the highest toll on COVID-19. As hospital gets to manage the surge of COVID-19 cases, it is important to standardize treatment standard and package for COVID-19. Until recently, in Indonesia, COVID-19 curative package in hospital is paid using a retrospective payment system (claims system) using a per-diem rate. Quantifying standard cost using an established retrospective claims dataset is important as a basis for standard formulation for COVID-19 package treatment, should COVID-19 be accommodated into the benefit package for Universal Health Coverage (UHC) under the National Health Insurance. Methods We estimated a standard cost for COVID-19 treatment using provider’s perspective. The analysis was conducted retrospectively using established national COVID-19 claims dataset during January 2020 until 2021. Utilizing individual-or-patient level analysis, claims profile were broken down per-patient, yielding descriptive clinical and care-related profile. Estimate of price and charge were measured in average. Moreover, indicators were regressed to the total charged price (in logarithmic scale) so as to find the predictors of cost. Results Based on the analysis of 102,065 total claims data received by MOH in 2020-2021, there is an average claim payment for COVID-19 in the amount of IDR 74,52 million (USD$ 5175). Significant difference exists in hospital tariffs or price to the existing claims data, indicating profit for hospital within its role in managing COVID-19 cases. Claim amount predictors were found to be associated with change of claim amount, including high level of severity, hospital class, intensive care room occupancy and ventilator usage, as well as mortality. Conclusion As COVID-19 pandemic shifts towards an endemic, countries including Indonesia need to reflect on the existing payment system and move towards a more sustainable payment mechanism for COVID-19. The COVID-19 payment system needs to be integrated into the existing national health insurance allowing bundled payment to become more sustainable, which can be achieved by comprehensively formulating the bundled payment package for COVID-19.

Suggested Citation

  • Ryan R. Nugraha & Mutia A. Pratiwi & Ruli Endepe Al-Faizin & Ardian Budi Permana & Ery Setiawan & Yuli Farianty & Kalsum Komaryani & Hasbullah Thabrany, 2022. "Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims data of COVID-19 in 2020-2021," Health Economics Review, Springer, vol. 12(1), pages 1-10, December.
  • Handle: RePEc:spr:hecrev:v:12:y:2022:i:1:d:10.1186_s13561-022-00392-w
    DOI: 10.1186/s13561-022-00392-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1186/s13561-022-00392-w
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1186/s13561-022-00392-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:12:y:2022:i:1:d:10.1186_s13561-022-00392-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.